Search details
1.
Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach.
Drug Metab Dispos
; 47(7): 724-731, 2019 07.
Article
in English
| MEDLINE | ID: mdl-31028057
2.
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.
Br J Clin Pharmacol
; 78(3): 524-32, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-24606567
3.
Population Pharmacokinetics of Oral Migalastat in Adolescents and Adults With and Without Renal Impairment.
Clin Pharmacol Drug Dev
; 11(12): 1367-1381, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36331497
4.
Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects.
J Clin Anesth
; 66: 109899, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32585566
5.
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Cancer Chemother Pharmacol
; 85(4): 673-683, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32062691
6.
Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.
Cancer Chemother Pharmacol
; 77(4): 807-17, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26940938
7.
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.
J Clin Pharmacol
; 54(6): 696-706, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24408395
Results
1 -
7
de 7
1
Next >
>>